Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02148211 · ClinicalTrials.gov registry record

Fluarix/ FluLaval/ Fluarix Quadrivalent/ FluLaval Quadrivalent Vaccine Pregnancy Registry

A clinical trial of Influenza, sponsored by GlaxoSmithKline.

Completed
Registry status
507
Enrollment target
1
Study location

NCT02148211 is a study of Influenza that has completed, run by GlaxoSmithKline. The registered enrollment target is 507 participants, below the 36,801-participant average among 156 other Influenza trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02148211, a study of Influenza, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
507 participants
Enrollment target
1
Study location

Study Summary

The purpose of this pregnancy registry study is to detect and describe abnormal pregnancy outcomes in women intentionally or unintentionally vaccinated with any of GlaxoSmithKline (GSK) Biologicals' seasonal Inactivated Influenza Vaccines (sIIVs): Fluarix, FluLaval, Fluarix Quadrivalent and FluLaval Quadrivalent.

Conditions Studied

Interventions

  • OTHER Data collection

Study Locations (1)

North Carolina

  • GSK Investigational Site - Wilmington

Trial Details

FieldValue
Enrollment Target 507 participants
Start Date 2014-06-01
Est. Completion 2019-05-31

Sponsor

GlaxoSmithKline

1,345 total trials

What the Registry Record Tells You About NCT02148211

The ClinicalTrials.gov registry entry for NCT02148211 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 507 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,801-participant average among 156 other Influenza trials with a reported enrollment target (99% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 1 intervention - of which Data collection is the first listed.

NCT02148211 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT02148211 about?

NCT02148211 is a clinical study titled "Fluarix/ FluLaval/ Fluarix Quadrivalent/ FluLaval Quadrivalent Vaccine Pregnancy Registry". The purpose of this pregnancy registry study is to detect and describe abnormal pregnancy outcomes in women intentionally or unintentionally vaccinated with any of GlaxoSmithKline (GSK) Biologicals' seasonal Inactivated Influenza Vaccines (sIIVs): Fluarix, FluLaval, Fluarix Quadrivalent and FluLaval...

What is the current status of trial NCT02148211?

This trial is currently completed. The enrollment target is 507 participants. The study started on 2014-06-01. Estimated completion is 2019-05-31.

What conditions does trial NCT02148211 study?

This clinical trial studies the following conditions: Influenza.

What interventions are being tested in trial NCT02148211?

The interventions under investigation include: Data collection (OTHER).

Who is sponsoring clinical trial NCT02148211?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02148211 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Influenza

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.